David S. Morris, MD, FACS, presented “Upper Tract Urothelial Cancer: Challenges and Opportunities for Treating the Unmet Medical Need” for the Grand Rounds in Urology audience in December 2019.
How to cite: Morris, David S. “Upper Tract Urothelial Cancer: Challenges and Opportunities for Treating the Unmet Medical Need” December, 2019. Accessed Dec 2024. https://dev.grandroundsinurology.com/upper-tract-urothelial-cancer-challenges-and-opportunities-for-treating-the-unmet-medical-need/
Upper Tract Urothelial Cancer: Challenges and Opportunities for Treating the Unmet Medical Need – Summary:
David S. Morris, MD, FACS, discusses current methods of diagnosing and risk-stratifying upper tract urothelial cancer (UTUC), as well as the implications of disease risk on treatment decisions. He notes the unmet need for an effective kidney-sparing option for low-risk patients, and the potential for chemoablation with UGN-101 to address this need based on findings from the OLYMPUS trial.
ABOUT THE AUTHOR
David S. Morris, MD, FACS, graduated summa cum laude from Vanderbilt University and earned his doctorate from Vanderbilt University School of Medicine in Nashville, Tennessee. Dr. Morris completed his residency training at the University of Michigan in Ann Arbor, Michigan, with a special research interest in genetics that predict the aggressiveness of prostate and bladder cancers. He authored and co-authored multiple scientific papers throughout his training and has presented research findings at regional and national meetings. He helps coordinate the genitourinary cancers program at Urology Associates’ Advanced Therapeutics Center as well as the Urology Associates Clinical Trials Program.
